GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Clinical Sciences / Institutionen för kliniska vetenskaper >
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper >

Development and application of a patient-derived xenograft platform to test anticancer agents


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/51878

Files in This Item:

File Description SizeFormat
gupea_2077_51878_1.pdfThesis frame43344KbAdobe PDF
View/Open
gupea_2077_51878_3.pdfAbstract572KbAdobe PDF
View/Open
Title: Development and application of a patient-derived xenograft platform to test anticancer agents
Authors: Einarsdottir, Berglind
E-mail: berglind.osk.einarsdottir@gu.se
Issue Date: 9-May-2017
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Clincial Sciences. Department of Surgery
Parts of work: I. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Berglind O. Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, Henrik Jesper-sen, Jan Mattsson, Lisa M. Nilsson, Katarina Truvé, Marcele Dávila López, Peter Naredi, Ola Nilsson, Ulrika Stierner, Lars Ny and Jonas A. Nilsson. Oncotarget 2014; 30;5(20):9609-18.
VIEW ARTICLE


II. Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts Joydeep Bhadury, Berglind O. Einarsdottir, Agnieszka Podraza, Roger Olofsson Bagge, Ulrika Stierner, Lars Ny, Marcela Dávila López and Jonas A. Nilsson. Oncotarget. 2016 Apr 26;7(17):23801-11
VIEW ARTICLE


III. TH1579 (Karonudib) inhibits MTH1 and microtubule dynamics and has broad anti-melanoma effects in patient-derived xenografts. Berglind O. Einarsdottir, Joakim Karlsson#, Elin MV Söderberg#, Mattias F. Lind-berg, Lydia C. Green, Elisa Funck-Brentano, Roger Olofsson Bagge, Henrik Jes-persen, Annika Thorsell, Carina Sihlbom, Louise Carstam, Martin Scobie, Tobias Koolmeister, Olof Wallner, Ulrika Stierner, Ulrika Warpman Berglund, Lars Ny, Lisa M. Nilsson, Erik Larsson, Thomas Helleday and Jonas A. Nilsson. #Equal contribution. Manuscript
Date of Defence: 2017-05-26
Disputation: Fredagen den 26 Maj 2017, kl. 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: malignant melanoma
patient-derived xenografts
MTH1
pre-clinical trial
Karonudib
Abstract: Malignant melanoma is the most aggressive form of skin cancer and incidence rates are on the rise. Despite recent improvements in treatment options, the disease still remains lethal. Which calls for expedited solutions. In this thesis I will discuss three studies, which have not only contributed new knowledge to the research community but also led to development of tools used in cancer research. In the first paper we developed a platform of patient-derived xenografts (PDXes) from metastat... more
ISBN: 978-91-629-0162-2 (PDF)
978-91-629-0161-5 (PRINT)
URI: http://hdl.handle.net/2077/51878
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper

 

 

© Göteborgs universitet 2011